THERAPEUTICS
5-day and 3-day oral prednisolone did not differ for asthma control in children who had acute asthma exacerbations
| The first 150 words of the full text of this article appear below. |
A B Chang
Professor A B Chang, Queensland Children's Respiratory Centre, Brisbane, Queensland, Australia; annechang@ausdoctors.net
STUDY DESIGN
randomised controlled trial. Australian Clinical Trials Registry ACTRN012605000305628.
concealed.*
blinded (children, parents, and healthcare providers).*
STUDY QUESTION
emergency departments (EDs) in 3 hospitals in Queensland, Australia.
201 children 2–15 years of age (mean age 5 y, 60% boys) who presented to the ED between 7:30 am and 5 pm with acute exacerbation (needing >1 dose of salbutamol in 1 h) of asthma (>2 episodes of wheeze or dyspnoea with decreased respiratory rate and work of breathing in response to salbutamol) and were not admitted to hospital. Exclusion criteria were underlying respiratory disease, cerebral palsy or severe neurodevelopmental abnormality, immunodeficiency, prior enrolment in the study, use of oral corticosteroids, or very severe asthma requiring hospital admission, continuous nebulisation, or intravenous salbutamol.
oral prednisolone, 1 mg/kg to a maximum 50 mg/day, given for 5 days (n = 100) or
Columbia University Medical Center, New York, New York, USA
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
